Measurement of Serum Bactericidal Activity Specific forHaemophilus influenzaeType b by Using a Chromogenic and Fluorescent Metabolic Indicator
- 1 January 2004
- journal article
- Published by American Society for Microbiology in Clinical and Vaccine Immunology
- Vol. 11 (1) , 89-93
Abstract
We evaluated alamarBlue as a metabolic indicator in a standardized assay for the measurement of serum bactericidal activity (SBA) toHaemophilus influenzaetype b (Hib) using sera containing natural and vaccine-induced anticapsular (polyribosylribitol phosphate) antibodies. SBA assays with a colorimetric and a fluorometric end point in the presence of alamarBlue were developed and compared to a standard SBA assay, where colony counts are performed to determine the titer (12). A colorimetric end point required a spectrophotometer, whereas a fluorometric end point required a fluorometer. Prevaccination sera (n= 27) and postvaccination sera (n= 13) were tested by all three methodologies, and the SBA titers obtained in the presence of alamarBlue were compared to those from the standard method. Both the colorimetric and the fluorometric SBA titers were significantly correlated (r= 0.87 andr= 0.95, respectively) with those of the standard assay (≥50% killing as the SBA titer end point), and titers were not significantly different when compared to those of the standard assay (P> 0.68). However, the fluorometric end point had superior performance and ease of titer determination compared to the colorimetric end point (95 versus 87% of SBA titers were within 2 dilutions of the standard titer). Hib SBA assays with alamarBlue are reproducible, faster (same-day assay), and easier to perform than the standardized assay, which requires manual or automated colony counts. These semiautomated methodologies result in increased sample throughput and collection of data in digital formats that can be exported to data analysis programs for determination of SBA titers.Keywords
This publication has 15 references indexed in Scilit:
- Summary of notifiable diseases--United States, 2000.2002
- Functional Antibody Activity Elicited by Fractional Doses ofHaemophilus influenzaeType b Conjugate Vaccine (Polyribosylribitol Phosphate–Tetanus Toxoid Conjugate)Clinical and Diagnostic Laboratory Immunology, 2001
- Reemergence of InvasiveHaemophilus influenzaeType b Disease in a Well‐Vaccinated Population in Remote AlaskaThe Journal of Infectious Diseases, 1999
- Haemophilus influenzae type B infection.1998
- Progress toward elimination of Haemophilus influenzae type b disease among infants and children--United States, 1987-1995.1996
- A new rapid and simple non-radioactive assay to monitor and determine the proliferation of lymphocytes: an alternative to [3H]thymidine incorporation assayJournal of Immunological Methods, 1994
- Avidity and bactericidal activity of antibody elicited by different Haemophilus influenzae type b conjugate vaccines. The Vaccine Study Group.1992
- Avidity and Bactericidal Activity of Antibody Elicited by Different Haemophilus influenzae Type b Conjugate VaccinesJAMA, 1992
- The Protective Level of Serum Antibodies to the Capsular Polysaccharide of Haemophilus influenzae Type bThe Journal of Infectious Diseases, 1983
- Induction of SerumHaemophilus influenzaeType B Capsular Antibodies in Adult Volunteers Fed Cross-ReactingEscherichia coli075:K100:H5New England Journal of Medicine, 1975